Biotechnology Industry

Members of Parliament invested in the Biotechnology Industry

35 investments

25 companies

Investors

Filed	Name	Company	Pur. £	Cur. £	P/L %	MPV*
Jun '22	Lord Sugar	Acl / NMS:ACLX	£17.47	£115.07	558.67%	£461,070.43
Mar '24	Lord Moynihan of Chelsea	Candel Therapeutics / NGM:CADL	£1.40	£8.16	482.86%	£407,999.99
Mar '24	Lord Moynihan of Chelsea	Tg Therapeutics / NCM:TGTX	£15.05	£48.05	219.27%	£223,488.37
May '22	Lord Reay	Novo Nordisk As / NYQ:NVO	£56.40	£140.80	149.67%	£174,767.27**
Mar '24	Lord Petitgas	Royalty Pharma / NMS:RPRX	£30.08	£55.29	83.81%	£128,666.89
May '22	Lord Triesman	Blue / NMS:BLUE	£3.39	£4.97	46.61%	£102,625.36
Mar '24	Lord Moynihan of Chelsea	Fortress Biotech / NCM:FBIO	£1.92	£2.76	43.75%	£100,625.00
Aug '23	Lord Nash	Relay / NGM:RLAY	£10.62	£14.24	34.09%	£93,860.64
Jul '25	Lord Fink	Avacta Group / LSE:AVCT.L	£51.50	£68.50	33.01%	£93,106.80
Nov '21	Lord Sherbourne of Didsbury	Novo Nordisk As / NYQ:NVO	£56.71	£70.73	24.73%	£87,313.29**
Apr '21	Baroness Deech	Novo Nordisk As / NYQ:NVO	£36.35	£43.96	20.94%	£84,654.75
Dec '22	Lord Hintze	Atai Life Sciences / NGM:ATAI	£3.48	£3.87	11.21%	£77,844.83**
Jun '16	Lord Lloyd-Webber	Bb Biotech / EBS:BION.SW	£47.80	£42.80	-10.46%	£62,677.82
Nov '24	Lord Moynihan of Chelsea	Sab Biotherapeutics / NCM:SABS	£3.95	£3.38	-14.43%	£59,898.74
Mar '14	Lord Glendonbrook	Bb Biotech / EBS:BION.SW	£33.36	£27.20	-18.47%	£57,074.34**
Apr '22	Lord Hylton	Genus / LSE:GNS.L	£2,678.00	£2,170.00	-18.97%	£56,721.43
Mar '17	Lord Lloyd-Webber	Bb Biotech / EBS:BION.SW	£54.95	£42.80	-22.11%	£54,522.29
Mar '24	Lord Moynihan of Chelsea	Mustang Bio / NCM:MBIO	£1.04	£0.80	-23.27%	£53,711.54
May '23	Lord Stevens of Ludgate	Avacta Group / LSE:AVCT.L	£112.00	£68.50	-38.84%	£42,812.50
Apr '24	Lord Grabiner	Novo Nordisk As / NYQ:NVO	£127.46	£64.73	-49.22%	£35,549.19**
Mar '24	Lord Petitgas	Moderna / NMS:MRNA	£111.98	£49.64	-55.67%	£31,030.54
Nov '23	Lord Mance	Novo Nordisk As / NYQ:NVO	£101.69	£43.96	-56.77%	£30,260.59
Apr '22	Lord Spencer of Alresford	Oxford Nanopore / LSE:ONT.L	£320.00	£120.00	-62.50%	£26,250.00
Jan '21	Lord Spencer of Alresford	Immupharma / LSE:IMM.L	£12.65	£4.56	-63.93%	£25,249.80
Apr '24	Lord Willoughby de Broke	Novo Nordisk As / NYQ:NVO	£122.75	£43.96	-64.19%	£25,068.84
May '24	Lord Londesborough	Novo Nordisk As / NYQ:NVO	£134.66	£43.96	-67.35%	£22,851.63
Sep '21	Lord Darzi of Denham	Oxford Nanopore / LSE:ONT.L	£612.60	£120.00	-80.41%	£13,712.05
Oct '15	Lord Hayward	Sage / NGM:SAGE	£46.11	£8.68	-81.18%	£13,177.19
May '11	Lord Glendonbrook	Mesoblast / NMS:MESO	£101.20	£14.12	-86.05%	£9,766.80
Apr '19	Lord Nash	Eq / NCM:EQ	£8.20	£0.69	-91.59%	£5,890.24**
Mar '23	Baroness Shields	Benevolentai / AMS:BAI.AS	£2.46	£0.09	-96.14%	£2,703.25**
May '20	Lord Wolfson of Aspley Guise	Adc Therapeutics / NYQ:ADCT	£30.00	£1.06	-96.47%	£2,473.33
Mar '24	Lord Moynihan of Chelsea	Avenue Therapeutics / NCM:ATXI	£12.00	£0.30	-97.50%	£1,750.00
Mar '24	Lord Moynihan of Chelsea	Adaptimmune / NMS:ADAP	£1.47	£0.03	-98.28%	£1,207.14**
Dec '22	Lord Hintze	Affimed / NGM:AFMD	£21.20	£0.18	-99.14%	£599.29**

* Minimum Potential Value based on £70,000.00 invested at time of declaration.

** Interest ceased/exited on filed date.